VEOZA (Astellas Pharma Australia Pty Ltd)
Product name
VEOZA
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
fezolinetant
Registration type
NCE/NBE
Indication
VEOZA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see section 5.1 Pharmacodynamic Properties – Clinical Trials).